LEXINGTON, Mass., Dec. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced an upcoming presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 9, 2017, in Atlanta. This presentation will provide an analysis of results from the Phase 2 trial of CUDC-907.
|Date/Time:||Saturday, Dec. 9, 5:30 p.m. – 7:30 p.m. EST|
|Presentation Title:||Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907|
|Location:||Building A, Level 1, Hall A2, Georgia World Congress Center, Atlanta|
Additional information on the poster presentation can be accessed at https://ash.confex.com/ash/2017/webprogram/Paper104454.html.
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer